Gynecologic Cancer News

Women aged 65 years or younger who underwent surgery and adjuvant chemotherapy for gynecologic cancer appeared at higher risk for osteopenia and osteoporosis as early as 1 year after treatment, according to study results presented at the virtual Society of Gynecologic Cancer Annual Meeting.

Breastfeeding appeared to be associated with reduced risk for overall ovarian cancer and for the high-grade serous subtype, according to results of a pooled analysis published in JAMA Oncology.

A novel blood test accurately detected more than 50 types of cancer with a specificity of 99.3%, according to results of the prospective Circulating Cell-free Genome Atlas study published in Annals of Oncology.

Women who underwent minimally invasive radical hysterectomy for early-stage cervical cancer demonstrated had higher risk for recurrence than women who had open surgery, according to results of a retrospective, multi-institutional review published in Journal of Clinical Oncology.

The FDA granted fast track designation to balstilimab in combination with zalifrelimab for the treatment of women with relapsed or refractory metastatic cervical cancer, according to the agents’ manufacturer.

The combination of cediranib and olaparib failed to extend PFS compared with platinum-based chemotherapy for a subset of women with ovarian cancer, according to topline results of a randomized phase 3 trial.

Today is International HPV Awareness Day.

The FDA accepted a supplemental new drug application for niraparib as first-line maintenance treatment of women with platinum-responsive advanced ovarian cancer.

The FDA approved neratinib as part of combination treatment of HER2-positive metastatic breast cancer, according to the agent’s manufacturer.

The FDA has taken three steps intended to increase safety of laparoscopic power morcellators when used in gynecologic surgeries, according to a statement released by the agency earlier today.